Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Oric Pharmaceuticals (ORIC) Shares Outstanding (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Shares Outstanding readings, the most recent being $103.5 million for Q1 2026.

  • Quarterly Shares Outstanding rose 45.59% to $103.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $103.5 million through Mar 2026, up 45.59% year-over-year, with the annual reading at $98.5 million for FY2025, 38.73% up from the prior year.
  • Shares Outstanding hit $103.5 million in Q1 2026 for Oric Pharmaceuticals, up from $98.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $103.5 million in Q1 2026 and bottomed at $39.4 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $65.1 million, with a median of $67.4 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding grew 0.62% in 2022 before it soared 49.52% in 2024.
  • Oric Pharmaceuticals' Shares Outstanding stood at $45.1 million in 2022, then increased by 21.68% to $54.9 million in 2023, then increased by 29.45% to $71.0 million in 2024, then surged by 38.73% to $98.5 million in 2025, then rose by 5.03% to $103.5 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Shares Outstanding are $103.5 million (Q1 2026), $98.5 million (Q4 2025), and $97.3 million (Q3 2025).